6738 Background: During the period of 1992-September 2003, 97 cases of CML were studied, of those 60 were male patients and 37 female patients. Age varied from 12 to 72 years. 8 patients refused treatment after diagnosis and 43 patients discontinued after few months < 12 months. METHOD MEDIAN SURVIVAL. NAME OF DRUGS NO. OF PATIENTS SURVIVAL IN MONTHS. Busulphan 2 26.5 Hydroxyurea 27 32.2 Busulphan -> Hydroxyurea 3 36 Busulphan -> Hydroxyurea -> Interferon A 3 41 Hydroxyurea -> Interferon A 8 42.7 Imatinib 6 - Result: Of those who received regular treatment 7 survived 5 years (16.3%) with Median Survival 77.4 months. 5 patients were treated with Hydroxyurea and survived 75.4 months. 2 patients were treated with Hydroxyurea + Interferon A survived 82.5 months. All 7 patients had complete hematological response -WBC < 10000,Spleen not palpable and Cytogenetic investigations were not done due to lack of required facility.6 patients started receiving capsule Imatinib 400mg daily since March 2003. All patients are alive and continuing the treatment. It is too early to make any conclusions regarding survival duration of these patients. CONCLUSION Our study suggests 1) Hydroxyurea + Interferon A give better survival for CML patients. 2) More time is necesarry to observe the results of Imatinib. No significant financial relationships to disclose.